Company Profile
Fate Therapeutics Stock Price, News & Analysis
- Ticker:
- FATE
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
2.43 USD (+0.83%)
Close
Last updated: July 27, 2026
300M USD
Market cap
Why the stock is moving
As of Jul 27, 2026, FATE closed up 0.83% at $2.43. No new same-company headline was identified in the current news window.
Company overview
Business overview
Fate Therapeutics is a cell-therapy company focused on engineered immune cells and off-the-shelf approaches to cancer and immune disease. Its strategy has long centered on platform ambition in cell therapy.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Fate sits in advanced cell therapy.
Business Model Characteristics
The company depends on platform validation, clinical data, and the ability to make engineered cell therapy commercially meaningful.
Position Within the Biotechnology Landscape
Fate is a high-catalyst cell-therapy name whose stock can react sharply to both scientific and strategic updates.
Future catalysts
The next few months for Fate Therapeutics are centered on its latest development priorities. The latest company update points to LN, a Phase 2 potentially registrational clinical trial of FT819 in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE) with lupus nephritis, on.... If that progress holds, the program should stay on the radar through the rest of the quarter.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK
GSK · Source: GSK plc
- 02
Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results
LEGN · Source: Legend Biotech Corporation
- 03
- 04
- 05
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
KYMR · Source: Kymera
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Fate Therapeutics (FATE)?
Fate Therapeutics (FATE) most recently closed at 2.43 USD, a +0.83% move versus the previous session.
What is the market cap of Fate Therapeutics (FATE)?
Fate Therapeutics currently has a market capitalization of 300M USD on BioPharmSignal.
What does Fate Therapeutics do?
Fate Therapeutics is a cell-therapy company focused on engineered immune cells and off-the-shelf approaches to cancer and immune disease. Its strategy has long centered on platform ambition in cell therapy.
On which exchange is FATE stock listed?
Fate Therapeutics (FATE) is associated with NASDAQ, United States, Biopharma.
What is Fate?
The next few months for Fate Therapeutics are centered on its latest development priorities.
Which conditions is Fate Therapeutics targeting with Fate?
Fate Therapeutics is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does Fate Therapeutics describe recent progress with Fate?
The next few months for Fate Therapeutics are centered on its latest development priorities.
What is Therapeutics?
Fate Therapeutics is a cell-therapy company focused on engineered immune cells and off-the-shelf approaches to cancer and immune disease.